JP4673871B2 - 赤血球用懸濁媒体 - Google Patents
赤血球用懸濁媒体 Download PDFInfo
- Publication number
- JP4673871B2 JP4673871B2 JP2007163346A JP2007163346A JP4673871B2 JP 4673871 B2 JP4673871 B2 JP 4673871B2 JP 2007163346 A JP2007163346 A JP 2007163346A JP 2007163346 A JP2007163346 A JP 2007163346A JP 4673871 B2 JP4673871 B2 JP 4673871B2
- Authority
- JP
- Japan
- Prior art keywords
- suspension medium
- amino acid
- red blood
- erythrocyte
- medium according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 73
- 239000006285 cell suspension Substances 0.000 title description 3
- 150000001413 amino acids Chemical class 0.000 claims abstract description 32
- 239000000725 suspension Substances 0.000 claims abstract description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 8
- 239000004471 Glycine Substances 0.000 claims abstract description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930024421 Adenine Natural products 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- 229960000643 adenine Drugs 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 4
- 229930010555 Inosine Natural products 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 229960003786 inosine Drugs 0.000 claims abstract description 4
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 4
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 239000011780 sodium chloride Substances 0.000 claims abstract description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940024606 amino acid Drugs 0.000 claims description 35
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 7
- -1 aliphatic amino acid Chemical class 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 229930182844 L-isoleucine Natural products 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 229960005190 phenylalanine Drugs 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000000499 gel Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 7
- 230000001788 irregular Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims (9)
- グリシン、L−バリン、L−メチオニン、L−ロイシン及びL−イソロイシンのアミノ酸の組み合わせからなり、前記アミノ酸の濃度がイオン強度を減少させるために必要な濃度より高いことを特徴とする、赤血球を必要とする分析技法において使用される赤血球試薬用懸濁媒体。
- さらに、リン酸緩衝液、塩化ナトリウム、グルコース、アデニン、保存剤及びEDTAを含有する、請求項1に記載の赤血球試薬用懸濁媒体。
- さらに、イノシン、シトレート、クエン酸及び重炭酸塩を含有する、請求項1又は2に記載の赤血球試薬用懸濁媒体。
- さらに、非極性脂肪族アミノ酸、芳香族アミノ酸、親水性アミノ酸、正、負又は中性電荷を有する極性アミノ酸及びイオウを含有するアミノ酸を含む、請求項1〜3のいずれか1項に記載の赤血球試薬用懸濁媒体。
- さらに、L−リジン、L−ヒスチジン、L−トリプトファン、L−アルギニン、L−トレオニン及びL−フェニルアラニンを含む、請求項1〜3のいずれか1項に記載の赤血球試薬用懸濁媒体。
- アミノ酸が、懸濁媒体又は希釈溶液の総容量オスモル濃度が100〜700ミリオスモル/kgの範囲となる濃度で存在する、請求項1〜5のいずれか1項に記載の赤血球試薬用懸濁媒体。
- カラム中のゲル又はマイクロチューブでの免疫血液学的分析技法における、請求項1〜6のいずれか1項に記載の赤血球試薬用懸濁媒体の使用。
- 赤血球試薬を必要とする免疫血液学的技法における、請求項1〜6のいずれか1項に記載の赤血球試薬用懸濁媒体の使用。
- 赤血球を必要とする分析技法における、請求項1〜6のいずれか1項に記載の赤血球試薬用懸濁媒体の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200601682A ES2264403B1 (es) | 2006-06-22 | 2006-06-22 | Medio de suspension de hematies. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008003089A JP2008003089A (ja) | 2008-01-10 |
JP4673871B2 true JP4673871B2 (ja) | 2011-04-20 |
Family
ID=37813916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007163346A Active JP4673871B2 (ja) | 2006-06-22 | 2007-06-21 | 赤血球用懸濁媒体 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8802385B2 (ja) |
EP (1) | EP1869977B1 (ja) |
JP (1) | JP4673871B2 (ja) |
CN (1) | CN101101293B (ja) |
ES (2) | ES2264403B1 (ja) |
HK (1) | HK1108027A1 (ja) |
MX (1) | MX2007007326A (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2784011T3 (es) | 2002-10-16 | 2020-09-21 | Streck Inc | Procedimiento y dispositivo para recoger y preservar las células para su análisis |
US8871434B2 (en) * | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US8968992B2 (en) * | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
ES2649572T3 (es) | 2009-02-18 | 2018-01-12 | Streck Inc. | Conservación de ácidos nucleicos fuera de las células |
US11864553B2 (en) | 2009-10-23 | 2024-01-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
CN101718783B (zh) * | 2009-11-25 | 2012-11-14 | 江阴力博医药生物技术有限公司 | 广谱抗人球蛋白卡的制备方法 |
CN101718785B (zh) * | 2009-11-25 | 2012-12-12 | 江阴力博医药生物技术有限公司 | 直接抗人球蛋白试剂卡的制备方法 |
CN101718784B (zh) * | 2009-11-25 | 2013-01-09 | 江阴力博医药生物技术有限公司 | 新生儿溶血病检测试剂盒的制备方法 |
CN101718793B (zh) * | 2009-11-25 | 2013-03-20 | 江阴力博医药生物技术有限公司 | Rh血型分型卡的制备方法 |
CN101718786B (zh) * | 2009-11-25 | 2012-10-03 | 江阴力博医药生物技术有限公司 | 抗人球蛋白交叉配血卡的制备方法 |
CN101701961B (zh) * | 2009-11-25 | 2013-03-06 | 江阴力博医药生物技术有限公司 | Abo血型定型检测试剂卡的制备方法 |
CN101718794B (zh) * | 2009-11-25 | 2013-06-05 | 江阴力博医药生物技术有限公司 | ABO/RhD血型定型检测试剂卡的制备方法 |
CN102869364A (zh) * | 2010-02-16 | 2013-01-09 | 维亚塞尔有限责任公司 | 含有精氨酸的组合物和用于处理红细胞的方法 |
WO2011103177A1 (en) * | 2010-02-16 | 2011-08-25 | Viacell, Llc | Nucleoside-containing compositions and methods for treating red blood cells |
WO2013123030A2 (en) * | 2012-02-13 | 2013-08-22 | Streck, Inc. | Blood collection device for improved nucleic acid regulation |
CN103141472B (zh) * | 2013-03-19 | 2014-11-26 | 广西壮族自治区水产研究所 | 香港牡蛎精子超低温冷冻保存以及激活方法 |
WO2015013244A1 (en) | 2013-07-24 | 2015-01-29 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
CN106940377B (zh) * | 2017-03-14 | 2018-09-21 | 北京乐普医疗科技有限责任公司 | 一种凝胶悬浮缓冲液、由其处理得到的凝胶、检测卡及其应用 |
CA3117893A1 (en) * | 2018-11-19 | 2020-05-28 | Hemanext Inc. | Methods for the preservation of reagent red blood cells using carbon monoxide |
AR119906A1 (es) * | 2019-09-05 | 2022-01-19 | Hemanext Inc | Métodos para la conservación de glóbulos rojos reactivos utilizando monóxido de carbono |
CN112684192A (zh) * | 2020-12-25 | 2021-04-20 | 天津市宝坻区人民医院 | 缓血酸铵在abo血型反定型试剂盒中新用途 |
CN113812395A (zh) * | 2021-09-24 | 2021-12-21 | 合肥天一生物技术研究所有限责任公司 | 一种红细胞保存液 |
CN115590014A (zh) * | 2022-09-23 | 2023-01-13 | 无锡托马自然生物技术有限公司(Cn) | 一种红细胞保存液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6112626A (ja) * | 1984-06-28 | 1986-01-21 | Ajinomoto Co Inc | 血液保存剤 |
JPS6115838A (ja) * | 1984-06-29 | 1986-01-23 | Ajinomoto Co Inc | 血液保存剤 |
JP2004170127A (ja) * | 2002-11-18 | 2004-06-17 | Olympus Corp | 抗体試験のための血球試薬 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4259207A (en) * | 1979-09-19 | 1981-03-31 | American Hospital Supply Corporation | Suspending medium for immunologic reactions |
FR2577321B1 (fr) | 1985-02-08 | 1989-04-28 | Lapierre Yves | Dispositif et procede de mise en evidence d'agglutinats erythrocytaires |
US4774088A (en) * | 1986-01-08 | 1988-09-27 | The United States Of America As Represented By The Deptment Of Health And Human Services | Method and additives for improving the quality and shelf life of stored blood |
US4783401A (en) * | 1986-10-31 | 1988-11-08 | Smithkline Beckman Corporation | Viable cell labelling |
JPH087215B2 (ja) * | 1987-08-24 | 1996-01-29 | シュティフツング・フュア・ディアグノスティッシュ・フォルシュンク | 抗原および/又は抗体の検出方法および検出用の試験キット |
CA2055095C (en) * | 1990-11-09 | 2003-05-13 | Johnna B. Hawk | Column agglutination assay and device |
FR2687317B1 (fr) * | 1992-02-13 | 1995-06-23 | Aetsrn | Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique. |
ES2126521B1 (es) * | 1997-06-05 | 1999-11-16 | Transfusion De La Comunidad Va | Metodo para la deteccion de antigenos presentes en la membrana de hematies, propios o acoplados y de anticuerpos irregulares en muestras de suero. |
WO2002031122A1 (en) * | 2000-10-20 | 2002-04-18 | Massachusetts General Hospital | Plasma supplement and use in liver assist systems |
CA2516123A1 (en) * | 2003-02-17 | 2004-08-26 | Kiwi Ingenuity Limited | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
AU2005303388A1 (en) * | 2004-11-15 | 2006-05-18 | Inverness Medical Switzerland Gmbh | Blood type method system and device |
US9078428B2 (en) * | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
-
2006
- 2006-06-22 ES ES200601682A patent/ES2264403B1/es active Active
-
2007
- 2007-05-14 EP EP20070380137 patent/EP1869977B1/en active Active
- 2007-05-14 ES ES07380137.5T patent/ES2541135T3/es active Active
- 2007-06-13 CN CN200710111026.3A patent/CN101101293B/zh active Active
- 2007-06-18 MX MX2007007326A patent/MX2007007326A/es active IP Right Grant
- 2007-06-21 JP JP2007163346A patent/JP4673871B2/ja active Active
- 2007-06-22 US US11/766,934 patent/US8802385B2/en active Active
-
2008
- 2008-02-20 HK HK08101850.9A patent/HK1108027A1/xx unknown
-
2010
- 2010-10-29 US US12/915,346 patent/US20110045455A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6112626A (ja) * | 1984-06-28 | 1986-01-21 | Ajinomoto Co Inc | 血液保存剤 |
JPS6115838A (ja) * | 1984-06-29 | 1986-01-23 | Ajinomoto Co Inc | 血液保存剤 |
JP2004170127A (ja) * | 2002-11-18 | 2004-06-17 | Olympus Corp | 抗体試験のための血球試薬 |
Also Published As
Publication number | Publication date |
---|---|
ES2264403B1 (es) | 2007-11-01 |
MX2007007326A (es) | 2009-02-18 |
CN101101293B (zh) | 2013-03-06 |
CN101101293A (zh) | 2008-01-09 |
ES2541135T3 (es) | 2015-07-16 |
BRPI0702629A (pt) | 2008-02-19 |
JP2008003089A (ja) | 2008-01-10 |
ES2264403A1 (es) | 2006-12-16 |
US8802385B2 (en) | 2014-08-12 |
EP1869977B1 (en) | 2015-04-29 |
HK1108027A1 (en) | 2008-04-25 |
US20110045455A1 (en) | 2011-02-24 |
US20070298406A1 (en) | 2007-12-27 |
EP1869977A1 (en) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4673871B2 (ja) | 赤血球用懸濁媒体 | |
JP2977906B2 (ja) | 細胞の集団から希薄な細胞を分離する方法 | |
Rubin et al. | Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools | |
US5489386A (en) | Density gradient medium for the separation of cells | |
Kessler et al. | Dog erythrocyte antigens 1.1, 1.2, 3, 4, 7, and Dal blood typing and cross‐matching by gel column technique | |
JP6179508B2 (ja) | 希少細胞の検出方法 | |
US8889368B2 (en) | Use of ferrofluids for phenotyping blood and related applications | |
US7943368B2 (en) | Reducing time to result for blood bank diagnostic testing | |
USRE45617E1 (en) | Reference control for cell by cell analysis | |
TW201348707A (zh) | 一種輸血前配合試驗之試劑組及其試驗方法 | |
CN111713487B (zh) | 一种试剂红细胞保存体系及其制备方法 | |
JPH08501630A (ja) | 血液試験による疾病の確認に用いる保存した非感染性対照細胞 | |
CN105925670A (zh) | 膜测定方法 | |
EP1935903B1 (en) | Method for preserving human cell membrane antigen and human cell membrane | |
CN112684191A (zh) | 一种ABO血型正反定型及Rh血型检测卡及其制备方法 | |
CN112504793A (zh) | 用于渗透和固定血细胞的试剂及分析方法 | |
Wada et al. | Method of separation and concentration of fetal nucleated red blood cells in maternal blood and its application to fetal diagnosis | |
BRPI0702629B1 (pt) | Meio de suspensão para hemácias | |
Chagas et al. | Effect of red blood cell preservation by droplet freezing with non‐permeable cryoprotective agents in blood group antigen reactivity | |
Piety | Microfluidic and Paper-Based Devices for the Analysis of Red Blood Cells: Improving the Quality and Accessibility of Diagnosis, Monitoring and Treatment for Sickle Cell Disease | |
CN115144581A (zh) | 凝胶悬浮缓冲液、凝胶溶液以及检测卡及其用途 | |
CN117783547A (zh) | 血型检测试剂及血型检测试剂卡的制备方法 | |
Heinold et al. | SEQUENTIAL ANALYSIS BY IMMUNOPRECIPITATION-MALDI-TOF MASS SPECTROMETRY FOR DETECTION AND IDENTIFICATION OF ALLOANTIBODY SPECIFICITIES: 2321 | |
Vincenzi | PRELIMINARY RESULTS OF A SPECIES COMPARISON |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101227 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4673871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |